LUCA Science Inc.
Rick Tsai serves as the Chief Executive Officer at LUCA Science Inc. since July 2020 and is a Venture Partner at Axil Capital Partners and Axil Capital Advisors K.K. since June 2020. Previously, Rick Tsai held various leadership roles, including Vice Chairman of the Medical Affairs Committee for Japan at PhRMA, Head of Medical Affairs and Executive Officer at Merck, and Medical Director for Japan, Taiwan, and Hong Kong at Allergan. Rick Tsai’s medical training includes a Doctor of Medicine from Columbia University Vagelos College of Physicians and Surgeons and a Doctor of Dental Medicine from Harvard School of Dental Medicine. Additional educational accomplishments include a Bachelor's in Psychobiology and East Asian Language and Culture from the University of Southern California, a Merck Emerging Leaders Program certification from Harvard Business School, and microsurgery training from the University of California, San Francisco.
LUCA Science Inc.
LUCA Science is at the forefront of a new kind of mitochondrial therapy that aims to restore cellular bioenergetics in malfunctioning or damaged tissues and organs. Using our patented iMIT technology, LUCA Science is creating a novel platform of highly functional mitochondria. We could boost bioenergetics and restore normal activities by supplyingintact and functional mitochondria to the affected tissues. The utilization of mitochondria as a biopharmaceutical agent would be groundbreaking for treating a wide range of unmet medical needs.